Adaptimmune therapeutics plc (ADAP)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Revenue

761

-

237

157

-

1,479

40,792

9,038

8,196

4,270

27,185

3,521

2,857

8,536

2,416

328

2,918

4,031

4,948

2,783

2,728

Operating expenses
Research and development

21,264

20,354

29,617

25,511

22,019

22,429

23,484

26,624

25,732

25,148

24,034

19,591

18,615

16,847

15,610

16,856

14,476

16,619

8,853

8,404

5,976

General and administrative

9,261

10,729

10,741

10,148

11,773

10,816

10,290

11,291

11,204

8,822

8,111

7,710

6,463

6,345

5,424

6,172

5,267

5,514

4,403

5,486

2,359

Total operating expenses

30,525

31,083

40,358

35,659

33,792

33,245

33,774

37,915

36,936

33,970

32,145

27,301

25,078

23,192

21,034

23,028

19,743

22,133

13,256

13,890

8,335

Operating loss

-29,764

-30,355

-40,121

-35,502

-33,792

-31,766

7,018

-28,877

-28,740

-29,700

-4,960

-23,780

-22,221

-14,656

-18,618

-22,700

-16,825

-18,102

-8,308

-11,107

-5,607

Interest income

730

448

615

757

952

1,044

606

540

659

779

705

506

240

271

289

291

259

254

235

188

110

Other income, net

937

631

291

-6,277

5,430

-4,976

-2,249

-15,406

7,130

1,488

3,602

3,224

430

-593

-61

607

1,049

1,015

1,851

-3,502

3,603

Total other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,713

Loss before income taxes

-28,097

-29,276

-39,215

-41,022

-27,410

-35,698

5,375

-43,743

-20,951

-27,433

-653

-20,050

-21,551

-14,978

-18,390

-21,802

-15,517

-16,833

-6,222

-14,421

-1,894

Income tax expense

70

88

87

65

2

135

133

102

127

-170

225

165

231

436

104

293

59

-75

20

147

51

Net loss attributable to ordinary shareholders

-28,167

-29,364

-39,302

-41,087

-27,412

-35,833

5,242

-43,845

-21,078

-

-

-

-

-

-

-

-

-16,758

-6,242

-14,568

-1,945

Deemed dividend on convertible preferred shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

2,229

6,434

Net loss attributable to ordinary shareholders

-

-

-

-

-

-

-

-

-

-27,263

-878

-20,215

-21,782

-15,414

-18,494

-22,095

-15,576

-16,758

-6,242

-16,797

-8,379

Net loss per ordinary share - Basic and diluted
Earnings Per Share, Basic

-

-

-0.06

-

-

-

0.01

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Earnings Per Share, Diluted

-

-

-0.06

-

-

-

0.01

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted (in dollars per share)

-0.04

-

-

-0.07

-0.04

-

-

-0.08

-0.04

-

-

-0.04

-0.05

-0.04

-0.04

-0.05

-0.04

-0.04

-0.01

-0.05

-0.05

Weighted average shares outstanding:
Weighted Average Number of Shares Outstanding, Basic

-

-

630,866

-

-

-

582,004

-

-

-

561,239

-

-

-

-

-

-

-

-

-

-

Weighted Average Number of Shares Outstanding, Diluted

-

-

630,866

-

-

-

621,764

-

-

-

561,239

-

-

-

-

-

-

-

-

-

-

Basic and diluted (in shares)

739,753

-

-

629,355

627,945

-

-

565,197

562,381

-

-

556,776

428,961

424,720

424,711

424,711

424,711

424,711

424,711

316,559

181,370

Development revenue
Revenue

-

-

237

157

-

-

1,678

9,038

-

-

-

-

-

-

-

-

-

-

-

-

-

License revenue
Revenue

-

-

-

-

-

-

39,114

-

-

-

-

-

-

-

-

-

-

-

-

-

-